In response: Genomic profile of breast cancer

References

• Plun-Favreau J , Svedman C , Valentine W , Rouzier R . Letter to the Editor: genomic profile of breast cancer. Expert Rev Pharmacoecon Outcomes Res 2015;15(3):393-94
   PubMed Web of Science ®Google Scholar
• Box GEP , Draper NR . 1987. Empirical Model Building and Response Surfaces. John Wiley & Sons; New York, NY
   Google Scholar
• Hillner BE , Smith TJ . Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991;324:160-8
   PubMed Web of Science ®Google Scholar
• Chen E , Tong KB , Malin JL . Cost-effectiveness of 70-gene MammaPrint. signature in node-negative breast cancer. Am J Manag Care 2010;16(12):e333-42
   PubMed Web of Science ®Google Scholar
• Yang M , Rajan S , Issa AM . Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. Cancer 2012;118(20):5163-70
   PubMed Web of Science ®Google Scholar
• Retel VP , Joore MA , Knauer M , et al. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and adjuvant! online for early breast cancer. Eur J Cancer 2010;46:1382-91
   PubMed Web of Science ®Google Scholar
• Retel VP , Joore MA , van Harten WH . Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance. Breast Cancer Res Treat 2012;131(2):627-36
   PubMed Web of Science ®Google Scholar
• Retel VP , Joore MA , Drukker CA , et al. Prospective cost-effectiveness analysis of genomic profiling in breast cancer. Eur J Cancer 2013;49(18):3773-9
   PubMed Web of Science ®Google Scholar
• Van de Vijver MJ , He YD , van’t Veer LJ , et al. A Gene-expression Signature as a Predictor of Survival in Breast Cancer. N Engl J Med 2002;347(25):1999-2009
   PubMed Web of Science ®Google Scholar
• Buyse M , Loi S , van’t Veer L , et al. Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. J Natl Cancer Inst 2006;98(17):1183-92
   PubMed Web of Science ®Google Scholar
• Mook S , Schmidt MK , Viale G , et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009;116(2):295-302
   PubMed Web of Science ®Google Scholar
• Wittner BS , Sgroi DC , Ryan PD , et al. Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort. Clin Cancer Res 2008;14(10):2988-93
   PubMed Web of Science ®Google Scholar
• Mook S , Schmidt MK , Weigelt B , et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010;21(4):717-22
   PubMed Web of Science ®Google Scholar
• Bueno-de-Mesquita JM , Linn SC , Keijzer R , et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 2009;117(3):483-95
   PubMed Web of Science ®Google Scholar
• Drukker C , Bueno-de-Mesquita JM , Retèl VP , et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013;133(4):929-36
   PubMed Web of Science ®Google Scholar
• Drukker CK , van Tinteren H , Schmidt MK , et al. Long Term Impact of the 70-gene Signature on Breast Cancer Outcome. Breast Cancer Res Treat 2014;143(3):587-92
   PubMed Web of Science ®Google Scholar
• Kunz G . Use of a genomic test (MammaPrint™) in daily clinical practice to assist in risk stratification of young breast cancer patients. Arch Gynecol Obstet 2011;283:597-602
   PubMed Web of Science ®Google Scholar
• Straver E . The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010;119(3):551-8
   PubMed Web of Science ®Google Scholar
• Whitworth P , Stork-Sloots L , de Snoo FA , et al. Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). Annals Surgical Oncology 2014;21(10):3261-7
   PubMed Web of Science ®Google Scholar
• Paik S , Shak S , Tang G , et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26
   PubMed Web of Science ®Google Scholar
• Carlson JJ , Roth JA . The impact of the Oncotype Dx Breast Cancer Assay in Clinical practice: systematic review and meta-analysis. Breast Cancer Res Treat 2013;141:13-22
   PubMed Web of Science ®Google Scholar
• Paik S , Tang G , Shak S , et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34
   PubMed Web of Science ®Google Scholar
• Knauer M , Mook S , Rutgers EJ , et al. The predictive value of the 70-gene MammaPrint signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120(3):655-61
   PubMed Web of Science ®Google Scholar
• Senkus E . Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(6):1-17
   Google Scholar
• Cusumano PG , Generali D , Ciruelos E , et al. European inter-institutional impact study of Mammaprint. Breast 2014;23(4):423-8
   PubMed Web of Science ®Google Scholar
• Denduluri N , Rugo HS , Davis SE , et al. Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts). J Clin Oncol 2011;29(suppl 27; Abstract 13
   Web of Science ®Google Scholar
• Poulet B , Jamshidian F , Butler S , et al. Risk classification of early stage breast cancer as assessed by MammaPrint and Oncotype DX genomic Assays. 2012 San Antonio Breast Cancer Symposium. Abstract # P6-07-03
   Google Scholar
• Shivers SC , Clark L , Esposito N , et al. Direct comparison of risk classification between MammaPrint®, Oncotype DX® and MammoStrat® assays With patients in early stage breast cancer. 2013 San Antonio Breast Cancer Symposium; Abstract # P6-07-03
   Google Scholar
• Estevez LG , Calvo I , Abad MF , et al. A retrospective study in the Spanish population with Oncotype DX recurrence score (RS) in breast cancer patients with positive and negative-lymph nodes. 2013 ASCO Annual Meeting. Abstract No. e11531
   Google Scholar